Transforming Tuberculosis Research with Microfluidics
Summary
Explore how microfluidics is advancing TB research, helping scientists achieve faster, more precise diagnostics and innovative drug discoveries. This study demonstrates how platforms like Cyto-Mine® can streamline the investigation of Mycobacterium tuberculosis, offering high-throughput single-cell analysis. These tools not only accelerate TB research but also reduce costs, enhance data quality, and support targeted drug screening. Discover how microfluidics is becoming essential in tackling one of the world’s most critical health challenges.
Research highlights
- Study Title: Microfluidics as a novel technique for tuberculosis: from diagnosis to drug discovery
- Authors: Molloy Antonia, James Harrison, John S. McGrath, Zachary Owen, Clive Smith, Xin Liu, Xin Li and Jonathan A. G. Cox
- Published In: Microorganisms, 2021
- DOI: 10.3390/microorganisms9112330
Key findings
- High-throughput TB diagnostics and drug discovery
- Accurate single-cell analysis via droplet microfluidics
- Potential for machine learning integration in TB research
The Next Generation: Cyto-Mine® Chroma
Automate. Accelerate. Analyze millions of cells in a single day.
Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.
Cyto-Mine® Chroma
Contact sales
